Publications by authors named "F A Hoffer"
Purpose: National Wilms Tumor Study-5 (NWTS-5) and AREN0321 evaluated the outcomes of children with rhabdoid tumor of the kidney (RTK) and malignant rhabdoid tumor of soft tissues (MRT).
Patients And Methods: Eligible patients with RTK were enrolled prospectively on NWTS-5 (1995-2002) and treated with carboplatin and etoposide alternating with cyclophosphamide (Regimen RTK). Patients with RTK or MRT were enrolled on AREN0321 (2005-2012) and received vincristine, doxorubicin, and cyclophosphamide alternating with carboplatin, cyclophosphamide, and etoposide (Regimens UH-1 or dose-reduced Revised UH-1).
Background: The International Neuroblastoma Risk Group (INRG) classifier utilizes a staging system based on pretreatment imaging criteria in which image-defined risk factors (IDRFs) are used to evaluate the extent of locoregional disease. Children's Oncology Group (COG) study ANBL0531 prospectively examined institutional determination of IDRF status and compared that to a standardized central review.
Methods: Between 9/2009-6/2011, patients with intermediate-risk neuroblastoma were enrolled on ANBL0531 and had IDRF assessment at treating institutions.
Article Synopsis
- The Children's Oncology Group AREN0534 Study aimed to enhance survival rates for children with bilateral Wilms tumors (BWT) through a brief preoperative chemotherapy regimen and personalized postoperative care based on tumor response.
- The study involved 180 children receiving specific chemotherapy drugs for either 6 or 12 weeks, followed by surgery, with follow-up treatments tailored to the tumor’s risk level.
- Results showed a strong 4-year event-free survival rate of 81% and overall survival rate of 95%, but patients with diffuse anaplasia had significantly lower survival rates, indicating the need for new strategies in treating this specific group.
Introduction: Diffuse hyperplastic perilobar nephroblastomatosis (DHPLN) represents a unique category of nephroblastomatosis. Treatment has ranged from observation to multiple regimens of chemotherapy. Wilms tumors (WTs) develop in 100% of untreated patients and between 32 and 52% of treated patients.
View Article and Find Full Text PDF